Hypertension and OMICS, quo vadis
- PMID: 38934187
- DOI: 10.1097/HJH.0000000000003765
Hypertension and OMICS, quo vadis
References
-
- Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217–223.
-
- Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol 2021; 18:785–802.
-
- Arnett DK, Claas SA. Omics of blood pressure and hypertension. Circ Res 2018; 122:1409–1419.
-
- Flaten HK, Monte AA. The pharmacogenomic and metabolomic predictors of ACE inhibitor and angiotensin II receptor blocker effectiveness and safety. Cardiovasc Drugs Ther 2017; 31:471–482.
-
- Baker PN, Myers JE. Preeclamptic toxemia: a disease ripe for proteomic discovery. Expert Rev Proteomics 2009; 6:107–110.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical